特例承認 against MSD K.K.
MSD株式会社 (医薬品医療機器等法)
医薬品医療機器等法Ministry of Health, Labour and WelfareDecember 24, 2021
Action summary
- Company
- MSD K.K.RomanizedOriginal: MSD株式会社
- Governing law
- 医薬品医療機器等法医薬品医療機器等法
- Action type
- 特例承認特例承認
- Action date
- December 24, 2021
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
Machine-translated summary — verify against original
Name of the COVID-19 treatment drug: Lagebrio Capsules 200mg, Generic name: Molnupiravir, Applicant: MSD Corporation, Application date: December 3, 2021 (Reiwa 3).
Show original Japanese text
新型コロナウイルス感染症に係る治療薬の販売名：ラゲブリオカプセル200mg、一般名：モルヌピラビル、申請者：MSD株式会社、申請日：令和３年12月３日
Source
Original Ministry of Health, Labour and Welfare announcement (in Japanese)The original Japanese disclosure is the authoritative record.
Watch this company
Get an email when MSD K.K. has new enforcement actions or registry changes (representative, address, business status). Sign-in is via a one-time email link — no password.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.